Ionis Pharmaceuticals Inc (NASDAQ:IONS) Chairman Stanley T. Crooke sold 22,000 shares of the company’s stock in a transaction dated Wednesday, January 3rd. The shares were sold at an average price of $50.01, for a total transaction of $1,100,220.00. Following the completion of the sale, the chairman now directly owns 58,014 shares of the company’s stock, valued at $2,901,280.14. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Shares of Ionis Pharmaceuticals Inc (NASDAQ IONS) opened at $49.89 on Friday. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25. The stock has a market capitalization of $6,174.88, a PE ratio of 332.62 and a beta of 2.86. Ionis Pharmaceuticals Inc has a twelve month low of $37.26 and a twelve month high of $65.51.

IONS has been the subject of a number of research analyst reports. Stifel Nicolaus reissued a “hold” rating on shares of Ionis Pharmaceuticals in a report on Tuesday, September 12th. Needham & Company LLC reissued a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a report on Sunday, September 17th. Barclays cut their price target on shares of Ionis Pharmaceuticals from $55.00 to $52.00 and set an “equal weight” rating for the company in a report on Thursday, September 21st. BMO Capital Markets reissued an “outperform” rating and issued a $69.00 price target on shares of Ionis Pharmaceuticals in a report on Monday, October 2nd. Finally, Goldman Sachs Group reissued a “sell” rating and issued a $30.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, October 6th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $50.76.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. AXA acquired a new stake in Ionis Pharmaceuticals during the 3rd quarter worth about $5,202,000. Steward Partners Investment Advisory LLC acquired a new stake in Ionis Pharmaceuticals during the 3rd quarter worth about $100,000. GSA Capital Partners LLP raised its holdings in Ionis Pharmaceuticals by 10.9% during the 3rd quarter. GSA Capital Partners LLP now owns 23,893 shares of the company’s stock worth $1,211,000 after buying an additional 2,348 shares during the period. Iguana Healthcare Management LLC acquired a new stake in Ionis Pharmaceuticals during the 3rd quarter worth about $761,000. Finally, Parallel Advisors LLC raised its holdings in Ionis Pharmaceuticals by 60.3% during the 3rd quarter. Parallel Advisors LLC now owns 3,323 shares of the company’s stock worth $182,000 after buying an additional 1,250 shares during the period. Hedge funds and other institutional investors own 91.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Ionis Pharmaceuticals Inc (IONS) Chairman Stanley T. Crooke Sells 22,000 Shares” was published by Watch List News and is the property of of Watch List News. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/ionis-pharmaceuticals-inc-ions-chairman-stanley-t-crooke-sells-22000-shares/1797343.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.